DUBLIN--(BUSINESS WIRE)--The "Low Grade Glioma Drug Profiles and Clinical Trials- Global Trends and Analysis Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.
This research provides comprehensive analysis and trends in global Glioma disease clinical trials. The research work analyzes the evolution of Glioma clinical trial trends across countries and regions.
The report focuses on drugs and therapies being evaluated for Glioma treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.
Scope of the Report:
- Number of Glioma clinical trials across regions - Asia and Oceania, Europe, Middle East Africa and Americas
- Trial information by Phase and Subjects recruited
- Trial information by status, type, sponsor type
- Drugs used for treatment of Glioma
- Both observational and interventional trials analyzed
- Success rates of trials are analyzed
- Trends in enrollment over the past ten years identified
Leading sponsors of Glioma clinical trials worldwide are listed
Key Topics Covered:
1 Table of Contents
2 Executive Summary
3 Low Grade Glioma Drugs in Ongoing and Completed Trials
4 Global Low Grade Glioma Clinical Trial Research Trends
5 Europe Low Grade Glioma Clinical Trial Research Trends
6 North America Low Grade Glioma Clinical Trial Research Trends
7 Western Pacific Low Grade Glioma Clinical Trial Research Trends
8 Recent Clinical Trials - Snapshots
For more information about this report visit https://www.researchandmarkets.com/research/qbc4m6/low_grade_glioma?w=4